Genetic Newborn Screening for Early-Onset Cancer Risk

Genomic newborn screening using heel-stick blood spots can identify infants at high risk for early-onset cancers before symptoms appear, according to a Nature Communications study led by researchers from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Mass General Brigham, and collaborators. Analyzing archived samples from 1,948 children in Michigan who developed solid or central nervous system tumors by age eight, the team found pathogenic or likely pathogenic germline variants in 6.8% of the cohort using an 11-gene panel.

Retinoblastoma and Actionable Gene Variants

The strongest signal in the study emerged from retinoblastoma cases. According to the study, germline RB1 variants were found in 69 children, with 68 of those children later developing the disease. Furthermore, 80% of children with known bilateral retinoblastoma carried a detectable RB1 variant at birth.

Identifying these variants early allows for regular ophthalmologic exams. Lisa Diller, MD, co-senior author and vice chair of Pediatric Oncology at Dana-Farber, stated that finding an early tumor or pre-tumor saves children from more difficult-to-treat and sometimes fatal diagnoses. Children with germline RB1 variants who were identified in the study were diagnosed at a median age of nine months, compared to 23 months for those without detected variants.

Targeted Gene Panels for Specific Pediatric Cancers

The research focused on genes linked to childhood cancer predisposition syndromes where vetted surveillance or preventive care already exists. According to the study authors, the gene panel included RB1, RET, TP53, WT1, SMARCB1, SUFU, PTCH1, DICER1, APC, ALK, and PHOX2B.

The data showed distinct correlations across other tumor types as well. All six children who developed medullary thyroid carcinoma carried germline RET variants. Additionally, WT1 variants were detected in seven infants who later developed renal tumors, while TP53 variants appeared in 24 children who developed sarcomas, CNS tumors, and adrenal malignancies. Richard B. Parad, MD, MPH, co-senior author of the study, noted that sequencing DNA extracted from heel-stick samples provides a platform for identifying children at high risk for early cancer in order to institute vetted surveillance protocols.

Public Health Considerations and Limitations

While the retrospective study points toward moving certain pediatric cancers from symptomatic diagnosis to genetically guided surveillance, researchers emphasize several hurdles. According to the study authors, the work relied on archived samples from a single U.S. state and focused exclusively on children who already developed cancer, rather than a prospective population.

The evaluation utilized a limited 11-gene panel and excluded leukemia predisposition genes and autosomal recessive syndromes. Broader clinical implementation will require prospective evidence, ancestry-diverse validation, cost-effectiveness analyses, specialized counseling infrastructure, and careful management of psychosocial burdens.

Frequently Asked Questions

Does routine newborn screening currently test for cancer?

No. Traditional newborn screening uses heel-stick blood samples to identify rare metabolic and genetic conditions, but routine panels do not include DNA sequencing for cancer predisposition.

To read more about ongoing pediatric cancer research and preventive medicine breakthroughs, explore our latest reporting or subscribe to our newsletter for updates.